Sectors & IndustriesHealthcare

Best Healthcare Stocks to Buy Now (2025)

Top healthcare stocks in 2025 ranked by overall Due Diligence Score. See the best healthcare stocks to buy now, according to analyst forecasts for the healthcare sector.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best healthcare stocks to buy right now are:

Theravance Biopharma (NASDAQ:TBPH) is the #1 top healthcare stock out of 1103 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Theravance Biopharma (NASDAQ:TBPH) is: Value: B, Growth: A, Momentum: C, Sentiment: B, Safety: D, Financials: A, and AI: B.

Theravance Biopharma (NASDAQ:TBPH) has a Due Diligence Score of 39, which is 14 points higher than the healthcare sector average of 25. It passed 12 out of 33 due diligence checks and has average fundamentals. Theravance Biopharma has seen its stock return 74.57% over the past year, overperforming other healthcare stocks by 108 percentage points.

Theravance Biopharma has an average 1 year price target of $25.67, an upside of 82.42% from Theravance Biopharma's current stock price of $14.07.

Theravance Biopharma stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Theravance Biopharma, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Embecta (NASDAQ:EMBC) is the #2 top healthcare stock out of 1103 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Embecta (NASDAQ:EMBC) is: Value: A, Growth: A, Momentum: C, Sentiment: B, Safety: D, Financials: A, and AI: C.

Embecta (NASDAQ:EMBC) has a Due Diligence Score of 35, which is 10 points higher than the healthcare sector average of 25. It passed 12 out of 38 due diligence checks and has average fundamentals. Embecta has seen its stock lose -4.34% over the past year, overperforming other healthcare stocks by 29 percentage points.

Embecta has an average 1 year price target of $18.50, an upside of 33.09% from Embecta's current stock price of $13.90.

Embecta stock has a consensus Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Embecta, 50% have issued a Strong Buy rating, 0% have issued a Buy, 50% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Infusystem Holdings (NYSEMKT:INFU) is the #3 top healthcare stock out of 1103 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Infusystem Holdings (NYSEMKT:INFU) is: Value: C, Growth: B, Momentum: B, Sentiment: A, Safety: C, Financials: A, and AI: C.

Infusystem Holdings (NYSEMKT:INFU) has a Due Diligence Score of 29, which is 4 points higher than the healthcare sector average of 25. It passed 9 out of 33 due diligence checks and has average fundamentals. Infusystem Holdings has seen its stock return 57.62% over the past year, overperforming other healthcare stocks by 91 percentage points.

Infusystem Holdings has an average 1 year price target of $13.50, an upside of 30.56% from Infusystem Holdings's current stock price of $10.34.

Infusystem Holdings stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Infusystem Holdings, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 72 healthcare stocks that have issued dividends in the past year, the 3 healthcare stocks with the highest dividend yields are:

Select Medical Holdings (NYSE:SEM) has an annual dividend yield of 14.55%, which is 12 percentage points higher than the healthcare sector average of 2.08%. Select Medical Holdings's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Select Medical Holdings's dividend has not shown consistent growth over the last 10 years.

Select Medical Holdings's dividend payout ratio of 35.1% indicates that its high dividend yield is sustainable for the long-term.

Cryo Cell International (NYSEMKT:CCEL) has an annual dividend yield of 8.33%, which is 6 percentage points higher than the healthcare sector average of 2.08%.

Cryo Cell International's dividend payout ratio of -2,166.7% indicates that its high dividend yield might not be sustainable for the long-term.

Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 7.89%, which is 6 percentage points higher than the healthcare sector average of 2.08%.

Dominari Holdings's dividend payout ratio of -13.4% indicates that its high dividend yield might not be sustainable for the long-term.

Healthcare stocks were up 1.36% in the last day, and up 0.15% over the last week. Bioaffinity Technologies was the among the top gainers in the healthcare sector, gaining 55.13% yesterday.

bioAffinity Technologies shares are trading lower after the company priced a $4.8M public offering of ~1.92M shares or pre-funded warrants at $2.50 per share.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued healthcare stocks right now are:

Harmony Biosciences Holdings (NASDAQ:HRMY) is the most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 55 points higher than the healthcare sector average of 16. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has dropped -30.86% in the past year. It has overperformed other stocks in the healthcare sector by 2 percentage points.

Embecta (NASDAQ:EMBC) is the second most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Embecta has a valuation score of 57, which is 41 points higher than the healthcare sector average of 16. It passed 4 out of 7 valuation due diligence checks.

Embecta's stock has dropped -4.34% in the past year. It has overperformed other stocks in the healthcare sector by 29 percentage points.

Puma Biotechnology (NASDAQ:PBYI) is the third most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Puma Biotechnology has a valuation score of 43, which is 27 points higher than the healthcare sector average of 16. It passed 3 out of 7 valuation due diligence checks.

Puma Biotechnology's stock has gained 89.06% in the past year. It has overperformed other stocks in the healthcare sector by 122 percentage points.

52.17% of healthcare stocks rated by analysts are a strong buy right now. On average, analysts expect healthcare stocks to rise by 40.4% over the next year.

5.3% of healthcare stocks have a Zen Rating of A (Strong Buy), 12.13% of healthcare stocks are rated B (Buy), 46.64% are rated C (Hold), 24.62% are rated D (Sell), and 11.31% are rated F (Strong Sell).